Kidswell USA

Kids Well Bio (formerly Gene Techno Science) is a Japanese biotechnology company specializing in the development of biosimilars and regenerative medicine products. The company's business model is built on three pillars: a biosimilar business providing affordable treatments for chronic diseases, a regenerative medicine business utilizing its proprietary SHED (Stem cells from Human Exfoliated Deciduous teeth) platform, and a new drug development division. Kids Well Bio has successfully commercialized several biosimilars in Japan, including ranibizumab and adalimumab, and is currently advancing its SHED-derived therapies for pediatric and rare diseases. The company aims to address unmet medical needs in both pediatric and adult segments through innovative cell therapies and biologics.